The popular diabetes drug Januvia may contain traces of a probable carcinogen, but patients should keep using the medication because it could be dangerous to stop taking it, the U.S. Food and Drug ...

(Reuters) - Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a ...

Unichem has obtained tentative approval from the Food and Drug Administration for sitagliptin tablets in dosage strengths of 25 mg, 50 mg, and 100 mg The medication is a generic of Merck Sharpe and ...

Januvia (sitagliptin) is a prescription drug for type 2 diabetes that helps lower blood sugar when combined with diet and exercise. Medicare drug plans usually cover this drug. In fact, starting in ...

(The Center Square) – Negotiated lower Medicare costs for 10 popular prescription drugs went into effect Thursday. How much those savings will be passed on to Medicare Part D and applicable Advantage ...

In a report to the FDA, Merck says it has figured out how its blockbuster Type 2 diabetes drugs have become contaminated with nitrosamine. And the company has told the regulator that it can fix the ...

Aug 9 (Reuters) - The U.S. Food and Drug Administration said on Tuesday certain samples of sitagliptin, a compound in Merck's MRK.N diabetes drug Januvia, were contaminated with a possible carcinogen.

New data reveals that Januvia was as effective as Glucotrol in reducing blood sugar levels in patients with type 2 diabetes.Merck (NYSE: MRK) announced today its drug Januvia was as effective as the ...

After years of battling over the patents on blockbuster diabetes drug Januvia, Merck and its generic rival Viatris are ready to put the case to rest. In a recent filing with the U.S. District Court ...

Medicare negotiated prices for 10 common drugs, including Eliquis and Januvia, slashing list prices 38% to 79% effective January 1, 2026. For patients on high-cost drugs like Imbruvica or Stelara, the ...

NEW YORK (Reuters) - Aggressive marketing of Merck & Co.'s new first-in-class diabetes drug Januvia has led to a strong launch, according to data compiled by ImpactRx Inc., a market research company ...

Regulatory Recon: FDA Rejects Merck's Bid to Add Heart Data to Januvia Label Two Gilead HCV Drugs Approved for Pediatric Use (7 April 2017) Welcome to Regulatory Reconnaissance, your daily regulatory ...